Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 6.

https://doi.org/10.1182/blood-2025-6

Published: 2025

Journal Articles

A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies

Brandon Aubrey, Peter Miller, Timothy Graubert, Yi-Bin Chen, Rohiverth Guarecuco, Amir Fathi, Robert Hasserjian, Andrew Brunner

Blood (2025) 146 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2025-2086

Published: 2025

Journal Articles

Development of synthetic introns for selective elimination of U2AF1 mutant MDS

Qian Zhang, Kuan-Ting Lin, Christian Figueroa-Espada, Yuxi Ai, Salima Benbarche, Jeetayu Biswas, Robert Stanley, Cynthia Castro, Nina Fox, Sumit Rai, Matthew Walter, Timothy Graubert, Qing Feng, Rachel Darman, Daniel Heller, Robert Bradley, Omar Abdel-Wahab

Blood (2025) 146 (Supplement 1): 229.

https://doi.org/10.1182/blood-2025-229

Published: 2025

Journal Articles

Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients

Terrence Neal Wong, MDPhD, Jeffery M. Klco, MDPhD, Ryan Demeter, Christopher A. Miller, PhD, Allegra Petti, PhD, Nichole Havey, Robert Fulton, PhD, Sharon Heath, Elaine R Mardis, PhD, Peter Westervelt, MD PhD, John F. DiPersio, MD PhD, Matthew J. Walter, MD, John S. Welch, MD PhD, Timothy Graubert, MD, Richard K Wilson, PhD, Timothy J. Ley, MD, Daniel C. Link, MD

Blood (2015) 126 (23): 686.

https://doi.org/10.1182/blood.V126.23.686.686

Published: 2015

Journal Articles

A Phase I Study Of Azacitidine After Donor Lymphocyte Infusion For Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation

Armin Ghobadi, MD, Mark A. Fiala, BS, CCRP, Camille N. Abboud, MD, Amanda F Cashen, MD, Linda Eissenberg, PhD, Timothy Graubert, MD, Meagan A Jacoby, MD/PhD, Iskra Pusic, MD, Mark A. Schroeder, MD, Keith E. Stockerl-Goldstein, MD, Michael H. Tomasson, MD, Geoffrey L. Uy, MD, Ravi Vij, MD, Matthew J. Walter, MD, John F. DiPersio, MD, PhD, Peter Westervelt, MD, PhD

Blood (2013) 122 (21): 3320.

https://doi.org/10.1182/blood.V122.21.3320.3320

Published: 2013

Journal Articles

Allele-Specific Effects Of U2AF1 Mutations On Alternative Splicing

Theresa Okeyo-Owuor, Brian S. White, PhD, Dipika Mohan, Malachi Griffith, PhD, Matthew J. Walter, MD, Timothy Graubert, MD

Blood (2013) 122 (21): 2748.

https://doi.org/10.1182/blood.V122.21.2748.2748

Published: 2013

Journal Articles

The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AML

Terrence Neal Wong, MD PhD, Giridharan Ramsingh, M.D, Andrew Young, Dong Shen, Chris Miller, PhD, Tamara Lamprecht, B.S., Sharon Heath, Robert S. Fulton, Elaine R. Mardis, PhD, Li Ding, Peter Westervelt, MD, PhD, John Welch, PhD/MD, Matthew J. Walter, MD, Timothy Graubert, MD, John F. DiPersio, MD, PhD, Timothy J. Ley, MD, Todd E Druley, MD, PhD, Richard K Wilson, PhD, Daniel C. Link, MD

Blood (2013) 122 (21): 5.

https://doi.org/10.1182/blood.V122.21.5.5

Published: 2013

Journal Articles

Whole Genome Sequencing of Therapy-Related Acute Myeloid Leukemia

Giridharan Ramsingh, Dong Shen, Tamara Lamprecht, B.S., Sharon Heath, Robert S. Fulton, Elaine R. Mardis, PhD, Li Ding, Peter Westervelt, John S. Welch, Matthew J. Walter, MD, Timothy Graubert, John F. DiPersio, MD, PhD, Timothy J. Ley, MD, Richard K Wilson, Daniel C. Link

Blood (2012) 120 (21): 784.

https://doi.org/10.1182/blood.V120.21.784.784

Published: 2012

Journal Articles

Mutant U2AF1(S34F) Expression Alters Hematopoiesis in Mice

Cara L Lunn, Ph.D., Justin Tibbitts, MS MBA, James N Ley, Jin Shao, Timothy Graubert, MD, Matthew J. Walter, MD

Blood (2012) 120 (21): 553.

https://doi.org/10.1182/blood.V120.21.553.553

Published: 2012

Journal Articles

Sudemycin Selectively Inhibits Growth of Primary Murine Hematopoietic Cells Expressing Mutant U2AF1

Manorama Tripathi, PhD, Cara L Lunn, Ph.D., Theresa Okeyo-Owuor, Matthew J. Walter, MD, Thomas R Webb, Timothy Graubert

Blood (2012) 120 (21): 554.

https://doi.org/10.1182/blood.V120.21.554.554

Published: 2012

Journal Articles

Complete Sequencing and Comparison of 12 Normal Karyotype M1 AML Genomes with 12 t(15;17) Positive M3-APL Genomes

Blood (2011) 118 (21): 404.

https://doi.org/10.1182/blood.V118.21.404.404

Published: 2011

Journal Articles

Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome

Matthew J. Walter, Dong Shen, Jin Shao, Li Ding, Marcus Grillot, Michael McLellan, Robert Fulton, Heather Schmidt, Joelle Kalicki-Veizer, O'Laughlin Michelle, Peter Westervelt, John F. DiPersio, Elaine R Mardis, Richard Wilson, Timothy J Ley, Timothy Graubert

Blood (2010) 116 (21): 608.

https://doi.org/10.1182/blood.V116.21.608.608

Published: 2010

Journal Articles

KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial

Jason Gotlib, Daniel J. DeAngelo, Tracy I. George, Christopher L. Corless, Andrea Linder, Cheryl Langford, Catherine Dutreix, Stefan Gross, Zariana Nikolova, Timothy Graubert

Blood (2010) 116 (21): 316.

https://doi.org/10.1182/blood.V116.21.316.316

Published: 2010

Journal Articles

Detection of Novel Mutations In MDS/AML by Whole Genome Sequencing

Blood (2010) 116 (21): 299.

https://doi.org/10.1182/blood.V116.21.299.299

Published: 2010

Journal Articles

BRCA1 and BRCA2 Nucleotide Variants in Young Women with Therapy Related Acute Myeloid Leukemia.

Michael G. Martin, MD, Meagan Jacoby, MD, Jin Shao, Elena Deych, PhD, Timothy Graubert, MD, Matthew J. Walter, MD

Blood (2009) 114 (22): 1102.

https://doi.org/10.1182/blood.V114.22.1102.1102

Published: 2009

Journal Articles

Caspase-9: A Candidate Susceptibility Factor for Murine Alkylator-Induced Leukemia.

Yedda Li, Patrick Cahan, Masayo Izumi, Timothy Graubert, MD

Blood (2009) 114 (22): 1273.

https://doi.org/10.1182/blood.V114.22.1273.1273

Published: 2009

Journal Articles

A Genome-Wide Analysis to Identify Novel Susceptibility Loci for Therapy-Related Acute Myeloid Leukemia

Kenan Onel, MD, PhD, Jeffrey A Knight, Andrew D Skol, PhD, Thelma R Tennant, Mekhala Banerjee, Richard Walgren, MD, PhD, Jin Shao, James M Allan, MD, Michelle M Le Beau, PhD, Richard A Larson, MD, Timothy Graubert, MD, Nancy J Cox, PhD

Blood (2008) 112 (11): 432.

https://doi.org/10.1182/blood.V112.11.432.432

Published: 2008

Journal Articles

Bcl2, a Candidate Murine Therapy-Related Acute Myeloid Leukemia Susceptibility Factor, Exhibits Strain-Dependent and Alkylator-Responsive Expression.

Ryan Funk, BS, Patrick Cahan, Masayo Izumi, Timothy Graubert, MD

Blood (2008) 112 (11): 1499.

https://doi.org/10.1182/blood.V112.11.1499.1499

Published: 2008

Journal Articles

AML1 and Evi1: coconspirators in MDS/AML?

Timothy Graubert

Blood (2008) 111 (8): 3916–3917.

https://doi.org/10.1182/blood-2008-01-135376

Published: 2008

Journal Articles

A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.

Richard Walgren, MD, PhD, Crystal Dao, MA, Frederieke Kreisel, MD, Peter Westervelt, MD, PhD, Camille Abboud, MD, Timothy Graubert, MD, Amanda Cashen, MD, Geoffrey Uy, MD, Feng Gao, MD, John DiPersio, MD, PhD, Ravi Vij, MD

Blood (2007) 110 (11): 1451.

https://doi.org/10.1182/blood.V110.11.1451.1451

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies

Development of synthetic introns for selective elimination of U2AF1 mutant MDS

Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients

A Phase I Study Of Azacitidine After Donor Lymphocyte Infusion For Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation

Allele-Specific Effects Of U2AF1 Mutations On Alternative Splicing

The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AML

Whole Genome Sequencing of Therapy-Related Acute Myeloid Leukemia

Mutant U2AF1(S34F) Expression Alters Hematopoiesis in Mice

Sudemycin Selectively Inhibits Growth of Primary Murine Hematopoietic Cells Expressing Mutant U2AF1

Complete Sequencing and Comparison of 12 Normal Karyotype M1 AML Genomes with 12 t(15;17) Positive M3-APL Genomes

Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome

KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial

Detection of Novel Mutations In MDS/AML by Whole Genome Sequencing

BRCA1 and BRCA2 Nucleotide Variants in Young Women with Therapy Related Acute Myeloid Leukemia.

Caspase-9: A Candidate Susceptibility Factor for Murine Alkylator-Induced Leukemia.

A Genome-Wide Analysis to Identify Novel Susceptibility Loci for Therapy-Related Acute Myeloid Leukemia

Bcl2, a Candidate Murine Therapy-Related Acute Myeloid Leukemia Susceptibility Factor, Exhibits Strain-Dependent and Alkylator-Responsive Expression.

AML1 and Evi1: coconspirators in MDS/AML?

A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only